<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00129168</url>
  </required_header>
  <id_info>
    <org_study_id>KAN-979-01</org_study_id>
    <nct_id>NCT00129168</nct_id>
  </id_info>
  <brief_title>Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>An Open-Label, Phase I/II, Multicenter Dose Escalation Study of Zosuquidar, Daunorubicin, and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kanisa Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kanisa Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      Chemotherapy drugs use different ways to stop cancer cells from dividing so they stop growing
      or die. Zosuquidar may help daunorubicin and cytarabine kill more cancer cells by making
      cancer cells more sensitive to the drugs. It is not yet known whether daunorubicin and
      cytarabine are more effective with or without zosuquidar in treating acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:

      Phase I:

      To Evaluate the safety of different doses of zosuquidar.

      Phase II:

      This study is designed to study the safety and effectiveness of zosuquidar when given with
      daunorubicin and cytarabine in newly diagnosed AML patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Leukemia, Myeloid</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zosuquidar</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed acute myeloid leukemia

          -  Ages 55-75 years

        Exclusion Criteria:

          -  Acute promyelocytic leukemia (FAB M3)

          -  Patients must not have received prior chemotherapy for AML.

          -  Prior exposure to anthracycline

          -  Use of any investigational agent within 4 weeks prior to enrollment into the study

        For Phase II:

          -  Patients must be P-glycoprotein positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2005</study_first_submitted>
  <study_first_submitted_qc>August 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2005</study_first_posted>
  <last_update_submitted>March 28, 2008</last_update_submitted>
  <last_update_submitted_qc>March 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2008</last_update_posted>
  <keyword>Leukemia, Myeloid</keyword>
  <keyword>Relapse</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Zosuquidar</keyword>
  <keyword>Daunorubicin</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Acute</keyword>
  <keyword>AML</keyword>
  <keyword>Adult AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

